Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.

2.50
Hdl Handle:
http://hdl.handle.net/10541/70324
Title:
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.
Authors:
Morschhauser, F; Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Huglo, D; Martinelli, G; Paganelli, G; Zinzani, P; Rule, Simon; Liberati, A; Milpied, N; Hess, G; Stein, H; Kalmus, J; Marcus, R
Abstract:
A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 ((90)Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII, respectively, and 19% in group B, with CR/CRu rates of 24%, 39.5%, and 12%, respectively. Median progression-free survival was 5.9 months and 3.5 months in strata AI and AII, respectively, and 1.6 months in group B. Median overall survival was 21.4, 22.4, and 4.6 months in stratum AI, stratum AII, and group B, respectively. Two patients died from thrombocytopenic cerebral bleeding following administration of therapy. Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing.
Affiliation:
Department of Hematology, Centre Hospitalier Universitaire, Lille, France.
Citation:
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. 2007, 110 (1):54-8 Blood
Journal:
Blood
Issue Date:
1-Jul-2007
URI:
http://hdl.handle.net/10541/70324
DOI:
10.1182/blood-2007-01-068056
PubMed ID:
17387223
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMorschhauser, F-
dc.contributor.authorIllidge, Timothy M-
dc.contributor.authorHuglo, D-
dc.contributor.authorMartinelli, G-
dc.contributor.authorPaganelli, G-
dc.contributor.authorZinzani, P-
dc.contributor.authorRule, Simon-
dc.contributor.authorLiberati, A-
dc.contributor.authorMilpied, N-
dc.contributor.authorHess, G-
dc.contributor.authorStein, H-
dc.contributor.authorKalmus, J-
dc.contributor.authorMarcus, R-
dc.date.accessioned2009-06-12T13:51:19Z-
dc.date.available2009-06-12T13:51:19Z-
dc.date.issued2007-07-01-
dc.identifier.citationEfficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. 2007, 110 (1):54-8 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid17387223-
dc.identifier.doi10.1182/blood-2007-01-068056-
dc.identifier.urihttp://hdl.handle.net/10541/70324-
dc.description.abstractA prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 ((90)Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII, respectively, and 19% in group B, with CR/CRu rates of 24%, 39.5%, and 12%, respectively. Median progression-free survival was 5.9 months and 3.5 months in strata AI and AII, respectively, and 1.6 months in group B. Median overall survival was 21.4, 22.4, and 4.6 months in stratum AI, stratum AII, and group B, respectively. Two patients died from thrombocytopenic cerebral bleeding following administration of therapy. Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing.en
dc.language.isoenen
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCerebral Hemorrhage-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshLymphoma, Large B-Cell, Diffuse-
dc.subject.meshMale-
dc.subject.meshRecurrence-
dc.subject.meshRemission Induction-
dc.subject.meshSalvage Therapy-
dc.subject.meshSurvival Analysis-
dc.subject.meshYttrium Radioisotopes-
dc.titleEfficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Centre Hospitalier Universitaire, Lille, France.en
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.